Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.